Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results Meeting Abstract
| Authors: | Mar, N.; Petrylak, D. P.; Hoimes, C. J.; Rosenberg, J. E.; Flaig, T. W.; Gourdin, T. S.; Barata, P. C.; Henry, E.; Bilen, M. S.; George, S.; Rao, S.; Assikis, V. J.; Burgess, E. F.; Lewis, B. E.; Srinivas, S.; Gorla, S. R.; Meng, C.; Zhu, Y.; O'Donnell, P. H. |
| Abstract Title: | Study EV-103 cohort H: Neoadjuvant treatment with enfortumab vedotin (EV) monotherapy in cisplatin (cis)-ineligible patients (pts) with muscle invasive bladder cancer (MIBC)—3-year efficacy results |
| Meeting Title: | 2025 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 43 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2025 May 30-Jun 3 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2025-06-01 |
| DOI: | 10.1200/JCO.2025.43.16_suppl.4583 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: 4583 -- Source: Cinahl |
